

Company	Country / Region
5Y Capital	China
A*STAR	Singapore
A*STAR, Innovation & Enterprise (I&E)	Singapore
Aagami	United States
AbbVie	United States
Abogen Biosciences	China
Acuitas Therapeutics	Canada
Adaptive Capital Partners	Singapore
Adelaide University	Australia
Aevice Health	Singapore
Ainab Family Office	India
Ajinomoto	Japan
Alecta	Sweden
Alihealth, Alibaba Group	China
Alnylam Pharmaceuticals	United Kingdom
Alpha Blue Ocean	United Arab Emirates
AlphaSense	Singapore
Amgen	Singapore
AMS Planning	Japan
Anaxis Pharma	Australia
Andera Partners	France
Angelini Ventures	Singapore
Archimed	Singapore
Arogy Therapeutics	United States
Asahi Kasei Corporation	Japan
Asahi Kasei Therapeutics Corporation	Japan
Asia Regulatory Professionals Association (ARPA)	Singapore
Astellas Pharma	Japan
Astrum CRO	Spain
Atlatl Innovation	China
August Global Partners	Singapore
Auxilart	Japan
B Capital	China
Baerenkraft Therapeutics	United States
Bayland Capital	Hong Kong, S.A.R.
Beacon	United Kingdom
BeOne Medicines	China
Betta Pharmaceuticals	China
BeyondBridge&Co	Singapore
Bigbang Angels	Singapore
Bio-Rad Laboratories	United States
Bioai Innovations	India
Biochromatographix	China
BioCorteX	United Kingdom

BioGenes	Germany
Biolexis Therapeutics	United States
BioPark Regensburg	Germany
BioPharm Services	United Kingdom
BioPhorum	United Kingdom
BioResearchAI	South Korea
Bioscience Equity Partners	United Arab Emirates
Biosector	Japan
Biostate	Australia
Bluepharma Indústria Farmacêutica	Portugal
BNV	Japan
Boehringer Ingelheim Venture Fund	Hong Kong, S.A.R.
Brano Therapeutics	Singapore
Bravera Bio	United States
Bright Mega Capital Corporation	Canada
C-Biomex	South Korea
C-mo Medical Solutions	Portugal
CaSRevolution	Italy
CBC Group	Singapore
CD Capital	China
CEC Capital	China
Cerulean Capital	China
Chaanakya Capital	United States
Chiesi Farmaceutici	Italy
China Resources Sanjiu Medical & Pharmaceutical	China
Chugai Venture Fund	United States
Cisema	Hong Kong, S.A.R.
City of Hope	United States
Clarity Bio Systems	India
Clarivate/BioWorld	Australia
ClavystBio	Singapore
Consun	Hong Kong, S.A.R.
Cooley	China
Copenhagen Capacity	Denmark
Coronet Ventures	Singapore
Crane Biosciences	Singapore
Create Medicines	United States
CTIC Capital	United States
Cytodyn	United States
Daejoong Life Science	South Korea
Daiichi Sankyo	Japan
Davidson Capital Research	Singapore
DCF	Singapore
Debere	United Kingdom
Delos Capital	Hong Kong, S.A.R.

Desire Ventures	Canada
DG Ventures	Japan
Divamics	China
Dragonboat Biopharmaceutical	China
Duke-NUS Medical School	Singapore
DXY Insight Database	China
Dyne Therapeutics	United States
EDBI	Singapore
Eight Roads Venture	China
Eight Roads Ventures China	China
EirGenix	Taiwan, China
Elev8.vc	Singapore
Elonova	South Korea
Enterprise Singapore	Singapore
EQT Partners	Hong Kong, S.A.R.
Etcmby	United Kingdom
EuBiologics	South Korea
EverEx	South Korea
Evonik SEA	Singapore
Experimental Drug Development Centre (EDDC)	Singapore
F-Prime	United States
Facio BioTherapies	Australia
FAO Partners	Singapore
Fapon Biopharma	China
Ferrier Research Institute	New Zealand
FGK Clinical Research	Germany
ForesightRx (Division of MarksMan Healthcare)	Singapore
FoRx Therapeutics	Switzerland
Frontier Nexus Studio	Singapore
Gaia	Germany
GC Biopharma	South Korea
GCCL	South Korea
Geek Gene Technology	China
genapse	Denmark
GenBio	United States
Genertec Meheco	China
Genmab	United States
Gipfel Biotechnology	China
GL Capital	China
Glacex	United Kingdom
GlobalData Healthcare UK	Australia
GNT Pharma	South Korea
Gold Nest Capital	Singapore
Goldman Sachs	Hong Kong, S.A.R.
GondolaBio	United States
Good Startup	Singapore

Greenwillow Capital	Singapore
GRIP	Switzerland
HanchorBio	China
HealthCap	Sweden
Hitachi	Japan
HK WinHealth Pharma Group	Hong Kong, S.A.R.
HKSTP	Hong Kong, S.A.R.
HLC	China
Hokkaido System Science	Japan
Hokkaido University	Japan
Holsten Pharma	Germany
Huasai BioMed	China
Hudson Institute of Medical Research	Australia
Hummingbird Bioscience	Singapore
ID Capital	Singapore
ieumvc	South Korea
iGlobe Partners	Singapore
Inogroup	Germany
International Family Offices Alliance for Health	United Kingdom
International Vaccine Institute	South Korea
Interrete (Family Office)	Singapore
Iris Biotech	Germany
ITR Laboratories	Canada
Jazz Pharmaceuticals	United States
JIF Capital	Singapore
JNC Corporation	Japan
Johnson & Johnson	Singapore
K2 BioCapital	China
K3 Ventures	Singapore
Kaken Pharmaceutical	Japan
Kanaph Therapeutics	South Korea
Keyron	United Kingdom
KH Neochem	Japan
KP Healthcare Partners	China
Kuano	United Kingdom
Kyowa Kirin	Japan
Kyowa Kirin Ventures (CVC arm of Kyowa Kirin)	Japan
L.E.K. Consulting	China
Lafana Life Sciences	Saudi Arabia
Legend Capital	Singapore
Leo International Family Office	Singapore
Life Science Incubator	Australia
Life Sciences & Digital Health	Australia
Loma Therapeutics	Denmark
LongRiver Investments	China
Lonza Bioscience	Singapore

LRI	China
Luxna Biotech	Japan
Lyfe Capital	Singapore
M Venture Partners	Singapore
Malaghan Institute of Medical Research	New Zealand
Marubeni Pharmaceuticals Asia Pacific	Vietnam
Maruho	Japan
Mavin Ventures	India
Maxim Asset Management	Singapore
Mayne Pharma International	Australia
McKinsey & Consulting Company	China
medac	Germany
Med-Fine Capital	China
MedBridgeX	Thailand
MediMabBio	South Korea
MedinCell	France
MedTech Actuator	Singapore
Merak Ventures	Singapore
Mint Venture Partners	South Korea
Mitsubishi Corporation	Japan
Mitsubishi Gas Chemical Company	Japan
Mitsui Knowledge Industry	Japan
Moleac	Singapore
Moxie Clinical	United States
MPM Capital	Singapore
MSD	Singapore
MSD	Ireland
Murdoch University	Australia
Nair Ventures	India
Nanobiotix	United States
NanoPalm	Saudi Arabia
Nanoverity	United Kingdom
NATi	Singapore
National Taiwan University	Taiwan, China
National University of Singapore	Singapore
NEB China	China
Neumous	South Korea
Nippon Zoki Pharmaceutical	Japan
Nona Biosciences US	United States
North Carolina State University	United States
NorthX Biologics	Sweden
Novasign	Austria
Novo Holdings	Singapore
Novo Nordisk	China
Novotech	India
NTU	Singapore

NUS Medicine	Singapore
o2h Ventures	United Kingdom
Octave Capital	Singapore
OmniPulse Biosciences	United States
Oncovita	France
OneSource Specialty Pharma	India
Ophidion	United States
OPIS	Italy
Opus 132	United States
Origenis	Germany
OTR Therapeutics	China
Otsuka Pharmaceutical Factory	Japan
Pacific Bridge NY	United States
Panacea Capital	Singapore
Parexel International	China
Partex NV	Germany
Partex.AI Labs	Germany
Path Biotech	United States
Peking University	China
Perspectiv Ventures	Singapore
Pfizer	China
PharmCube	China
Phocus Pharmaceuticals	Canada
Polaris Partners	Singapore
Precision Biotech	China
Protect Animal Health	Taiwan, China
Proteina	South Korea
Protalix BioTherapeutics	Israel
Proxygen	Austria
PT. Etana Biotechnologies Indonesia	Indonesia
Pureland Global Venture	Singapore
Pythia Biotech	Taiwan, China
Quadria Capital Investment Management	Singapore
Quantom Biosciences	Belgium
QureGenAI (Suzhou) Biotechnology	China
Rakuten Medical	United States
RedFox Therapeutics	Singapore
ReWire Therapeutics	United Kingdom
RiboPro	Netherlands
Riverstone	South Korea
RNA Australia	Australia
Roche	Switzerland
Romulus Therapeutics	Singapore
Rosette Media	Singapore
Santen Pharmaceutical Asia	Singapore
SaniMed Science Group	United States

Sartorius Stedim Biotech	Germany
Sartorius Stedim Singapore	Singapore
Scendea (AUS)	Australia
SciClone Pharmaceuticals International (SG)	Singapore
Scout	United Kingdom
SeaX Ventures	United States
Senju Pharmaceutical	Japan
Senhwa Biosciences	Taiwan, China
Sensible Biotechnologies	United Kingdom
Sequencio Therapeutics	Hong Kong, S.A.R.
Servier	China
SG Growth Capital	Singapore
SGInnovate	Singapore
Shanghai Healthcare Capital	China
Shanghai Hongene Biotech Corporation	United States
Shanghai LIDE Biotech	China
Shanghai Synbio Innovation Center	China
Shenzhen Chipscreen Biosciences	China
Silverlake - Hanoi Bio High-Tech Park	Vietnam
Singapore Economic Development Board	Singapore
Single Use Support	Austria
Singlomics Biopharmaceuticals	China
SmartCella	Sweden
Solara Active Pharma Sciences	India
Space Pharmaceuticals	Switzerland
SparkLabs Taiwan	Taiwan, China
Sprim Global Investments	Singapore
Suzhou Ribo Life Science	China
Swanielle	Japan
Synapto Ventures	Singapore
Syneos Health	Singapore
Taiho Innovations	Japan
Taiwania Capital	Taiwan, China
Takeda	Singapore
Tasly Pharmaceutical Group	China
Teclison	United States
Tee & How IP Attorneys	China
Thea Open Innovation	France
The Bioforge	United States
The University of Queensland	Australia
ThermoFisher Scientific	Singapore
TIIM Healthcare	Singapore
Tiumbio	South Korea
Tk & Partners	Thailand
Trinity Innovation Bioventure Fund	Singapore
Trinity Lifesciences	Singapore

Uniphar	Ireland
University of Colorado	United States
University of Macau	China
University of Natural Resources and Applied Life Sciences	Austria
University of Zurich, Institute of Medical Genetics	Switzerland
UNSW	Australia
Value Angels Network	India
Valuence Ventures	United States
VantageX	Singapore
Vaxxirna	United States
Venrock	United States
Verdeya Research Laboratories	Singapore
Verge HealthTech Fund	Singapore
VerImmune	Singapore
Vertex Growth Fund	Singapore
Vertex Ventures	Singapore
VIB	Belgium
Vickers Venture Partners	Singapore
Vivo Capital	Taiwan, China
VMS Investment Group (HK)	Hong Kong, S.A.R.
Voronoi	United States
Wedo Venture Partners	Singapore
WEHI Ventures	Australia
Weixinkang Pharmaceutical	China
WEP Clinical	United Kingdom
WestGene Biopharma	China
Wintermute Biomedical	United States
Wuhan Kangfude Biotechnology	China
WuXi AppTec	China
Xeraya Capital	Malaysia
xSquared Capital	Singapore
YAFO Capital (Shanghai)	China
Zealand Pharma	United States
ZhongMei Capital	Hong Kong, S.A.R.